2 CDC reports on spread and toxicity of fentanyl

a couple of brief reports on opiates in the community.

1. MMWR reported that there was an outbreak of poisonings in people in San Francisco taking a counterfeit​ Norco (a combo of hydrocodone and acetaminophen, but with a sinister name)  --see http://www.cdc.gov/mmwr/volumes/65/wr/mm6516e1.htm?s_cid=mm6516e1. 7 cases were reported, with some differences in the apparent composition of the counterfeit drug: all had fentanyl (a potent synthetic opioid, 100x that of morphine, and a full m-opioid receptor agonist. fentanyl has high lipophilicity, allowing it to enter the CNS rapidly. it is not marketed as an oral pill, so its presence in pill form confirms its being illicit); some had promethazine (used for nausea/vomiting, motion sickness, and it may potentiate the opiate high), some trace amounts of cocaine and several with no detectable hydrocodone. details:

--the illicit drugs appeared very similar to the real thing, including the inscription "M367"
--patients present to the ER with lethargy, bradypnea, unresponsiveness

so, just an alert. there has been an increase in these illicit/counterfeit products over the past few years, with fentanyl often being part of the problem. and this counterfeiting seems to be more sophisticated, with pills that look pretty much identical to the legal drugs.

2. another DEA alert on fentanyl (see http://emergency.cdc.gov/han/han00384.asp​ ) which also highlights the increased street prevalence of products containing illicit fentanyl or acetyl-fentanyl (at this time, most of the fentanyl-related overdoses are from illicit/manufactured drug, not diverted pharmaceutical fentanyl). Fentanyl is often mixed with heroin to increase the high, but sometimes sold alone as a highly potent drug (sometimes with street name "China White"). a few points:

--drug seizures by the DEA have found dramatic increases in fentanyl: from 618 in 2012 to 945 in 2013 to 4,585 in 2014
-->80% of the drug seizures were in 10 states, from highest to lowest:
        --ohio (1245)
        --massachusetts (630)
        --pennsylvania (419)
        --maryland (311)
        --new jersey, kentucky, virginia, florida, new hampshire, indiana (all between 133 to 238)
--it often takes more than one dose of naloxone to revive a patient with a fentanyl overdose.

so, perhaps the most important issues are the increasing availability of fentanyl on the streets, and its high potency means that we may need to use more than one dose of naloxone to revive a patient. and, when we give naloxone to patients to have at home, we need to advise them/their supports that it may take more than one dose.

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more